{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:23:56Z","timestamp":1762507436440,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":348,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.5604\/01.3001.0012.0950","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T11:39:51Z","timestamp":1528803591000},"page":"661-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient"],"prefix":"10.1016","volume":"17","author":[{"given":"Sara Lo","family":"Menzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariachiara Di","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasio","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Contini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0012.0950_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-acting antivirals: the endgame for hepatitis C","volume":"24","author":"D\u2019Ambrosio","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.5604\/01.3001.0012.0950_bib0010","first-page":"153","article-title":"European Association for the Study of the Liver","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.0950_bib0015","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"Suppl. 5","key":"10.5604\/01.3001.0012.0950_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-14-S5-S2","article-title":"Update on epidemiology of HCV in Italy: focus on the Calabria Region","volume":"14","author":"Marascio","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.5604\/01.3001.0012.0950_bib0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0012.0950_bib0030","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.5604\/01.3001.0012.0950_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11908-017-0578-5","article-title":"Hepatitis C VirusGenotype 3: update on current and emergent therapeutic interventions","volume":"19","author":"Johnson","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"10.5604\/01.3001.0012.0950_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4292\/wjgpt.v7.i1.33","article-title":"Hepatitis C virus: A time for decisions. Who should be treated and when","volume":"7","author":"Attar","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.5604\/01.3001.0012.0950_bib0045","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.5604\/01.3001.0012.0950_bib0050","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/liv.13335","article-title":"Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)","volume":"37","author":"Sulkowski","year":"2017","journal-title":"Liver Int"},{"key":"10.5604\/01.3001.0012.0950_bib0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0168-8278(02)00140-X","article-title":"High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis","volume":"37","author":"Mangia","year":"2002","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.0950_bib0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijid.2014.08.011","article-title":"Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV\/ HCV co-infected cirrhotic woman","volume":"29","author":"Hasson","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.5604\/01.3001.0012.0950_bib0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: A randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0012.0950_bib0070","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.5604\/01.3001.0012.0950_bib0075","doi-asserted-by":"crossref","unstructured":"Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, et al. HCV viral load at baseline and at week 4 of telaprevir\/boceprevir based triple therapies are associated with virological outcome in HIV\/hepatitis C co-infected patients. J Clin Virol 2015; 32-5. doi: 10.1016\/ j.jcv.2015.10.010.","DOI":"10.1016\/j.jcv.2015.10.010"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:36:33Z","timestamp":1761647793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119304910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1665268119304910"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0012.0950","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0012.0950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}